

CURRICULUM VITAE

March 9, 2016

NAME: Marylou Behnke
Professor
Department of Pediatrics
University of Florida College of Medicine

BIRTH: September 1, 1950, Orlando, Florida

EDUCATION: BS, (Chemistry, with Honors), University of Florida,
Gainesville, Florida, 1972
M.D., University of Florida College of Medicine,
Gainesville, Florida, 1976
Intern, Shands Teaching Hospital, Gainesville, FL, 1976-77
Resident, Shands Teaching Hospital, Gainesville, FL, 1977-79
Fellow, Division of Neonatology, Department of Pediatrics, University
of Florida College of Medicine, Gainesville, FL, 1981-83

APPOINTMENTS: Assistant Professor and Chief Resident, Department of Pediatrics,
1979-80
Assistant Professor, Department of Pediatrics, 1980-81
Assistant Professor, Division of Neonatology, Department of
Pediatrics, University of Florida, 1983-89
Associate Professor, Division of Neonatology, Department of
Pediatrics, University of Florida, 1989-99
Professor, Division of Neonatology, Department of Pediatrics,
University of Florida, 1999-2013
Professor Emeritus, Division of Neonatology, Department of Pediatrics,
University of Florida, 2013-present
Pharmacy and Therapeutics Committee, 1979-81
Total Parenteral and Enteral Nutrition Committee, 1982-89
Medical Director, Newborn Nursery and Intermediate Care
Unit, 1983-89
University Senate, 1984-90, 2004-2006, 2007-2009
Co-Chair, Committee on Committees 2005-2006
Member, Committee on Committees 2005-2009
Medical Director, Regional Neonatal Intensive Care Center,
1985-89
Medical Director, Developmental Evaluation and Intervention
Program, 1989-2012 (Part H in 1993)
Perinatal Care Committee, 1985-89
Inter-intensive Care Committee, 1985-1988
Medical Liaison, Parent Support Group, 1985-89
Pediatric Area Administration Committee, 1985-89
Clinical Unit Chief's/Chief Resident's Committee, 1985-89
Pediatrics Resident Selection Committee, 1987-2002
Graduate Studies Faculty, 1988-2000
Masters: Riddle, 1986
Stebor, 1987
Miller, 1988
Polak, 1992
Harmon, 1989
Cross, 1989
Gutknecht, 1990
Palazzalo, 1991
Ringdahl, 1992
Lombardero-Tuttle, 1991
Cantwell, 1992
Trout, 1993

Doctoral: Syfrett, 1993
Treloar, 1990
Stewart, 1990
Moore, 1994
Holler, 1996
Hou, XXX

Adjunct Assistant Professor, College of Nursing, 1988-89
Adjunct Associate Professor, College of Nursing, 1989-1999
Adjunct Professor, College of Nursing, 1999-2000
Research Advisory Committee, University of Florida College of
Medicine, 1993-94
Research and Development Award Committee, Biological and Life
Sciences, Division of Sponsored Research, 1992, 1993
Substance Exposed Newborn Coalition, Florida Department of Health and
Rehabilitative Services, 1988-1989
Florida Epidemiology Work Group, Patterns and Trends of Alcohol and Drug
Abuse in Florida, 1989
Regional Prenatal Substance Abuse Task Force, Alachua County, FL, 1989-1990
Southeast Regional Neonatal Round Table, The Cocaine Baby, Ross
Laboratories, 1990
Alachua/Tri-County Division Health Professional Advisory Committee,
March of Dimes, 1989-91
Primary Care/Substance Abuse Linkage Initiative, Regional Workgroup, DHHS,
Office for Treatment Improvement, 1991
Community Team Training Institute, CSAP National Resource Center, 1994
North Central Florida Coalition for Drug Free Babies and Families, 1994-1996
NIH Special Review Committee on Human Development Research,
National Institute on Drug Abuse, 1991-96 (Committee
Chairperson 10/93; 2/94; 12/95-5/96)
NIH Special Review Committee, National Institute on Alcohol Abuse
and Alcoholism, ad hoc reviewer, 2/94; 4/97
NIH Special Review Committee, GCRC, ad hoc reviewer, Yale GCRC 7/97;
Miami GCRC 4/01
NIH Special Review Committee-Health and Developmental Consequences of
Prenatal Exposure to Methamphetamine, NIDA, Chair, 6/01
NIH Special Review Committee-Center Site Visit, NIDA, ad hoc reviewer, 10/01
Chair, NIH Human Development Research Subcommittee, National
Institute on Drug Abuse, Initial Review Group, 1996-98
Member, NIH Human Development and Aging 3 (HUD/3) Study
Section, 1998-1999
Member, NIH Biobehavioral and Behavioral Processes (BBBP-6) Study Section,
1999-2002
Consultant, Fogarty International Center/NIH, Brain Disorders and Cognitive
Function in Low and Middle Income Countries: Developing a Research
Agenda, June, 2002
NIH Special Emphasis Panel (ZRG1 SSS-C 06), NIDA, ad hoc reviewer, 7/03
NIH Special Review Committee-Brain Disorders in Developing Countries,
NINDS, ad hoc reviewer, 8/5-8/6/03
NIH Special Emphasis Panel (ZDA1 KXN-G 28), NIDA, ad hoc reviewer, 3/04
NIH Subcommittee (ZDA1 PXC-V (12)), NIDA, ad hoc reviewer, 12/04
NIH Treatment Research Subcommittee (NIDA-E 1), NIDA, ad hoc reviewer,
3/05, 10/05, 6/06
NIH Special Emphasis Panel (ZDA1 RXL-E 06 M), NIDA, ad hoc reviewer,
3/05
NIH Medication Development Research Subcommittee (NIDA-L 1), NIDA, ad
hoc reviewer, 6/08
NIH Special Emphasis Panel (ZDA1 MXH-H 22 1), NIDA, ad hoc reviewer,
6/08
NIH Special Emphasis Panel (ZDA1 GXM-A 08 2), NIDA, ad hoc reviewer,
3/12
Ad hoc reviewer for Death Studies, Neurotoxicology and Teratology,

Pediatrics, Journal of Developmental and Behavioral Pediatrics, Journal of Pediatrics, Journal of the American Medical Association, Infancy, Child Development, Clinical Pediatrics, American Journal of Obstetrics and Gynecology, Alcoholism: Clinical and Experimental Research, Archives of Disease in Childhood, Birth Defects Research Part B: Developmental and Reproductive Toxicology, Birth Defects Research Part A: Clinical and Molecular Teratology, Journal of Pediatric Psychology, Journal of Addiction Medicine, American Journal of Perinatology, Annals of Epidemiology, Journal of Depression and Anxiety, Developmental Psychobiology

Florida Interagency Coordinating Council for Infants and Toddlers, 1995-2006

Board member, Center for Research on Women's Health, 1998-2002

Surgery Chair Search Committee, College of Medicine, 2002

Professorial Tenure and Promotion Committee, College of Medicine, 2001-2004

Co-Chair, Faculty Development Committee, Department of Pediatrics, 2003

Member, Space Committee, Department of Pediatrics, 2008

Faculty Mentor, Department of Pediatrics, 2007-2012

OB-GYN Chair Search Committee, College of Medicine, 2008

Academic Personnel Board, 2011-2012

Center for Excellence in Early Childhood Studies, Key Faculty, 2010-present

EDITORIAL BOARDS: Death Studies, 1983-1994
Journal of Addiction Medicine, 2007-2012

HONORS & AWARDS: Alpha Lambda Delta, 1968-70
Alpha Epsilon Delta, 1968-72
Mortar Board, President, 1971-72
Savant - UF, 1971-72
Who's Who in American Colleges and Universities, 1971-72
University of Florida Hall of Fame, 1971-72
Phi Beta Kappa, 1972
BS (with Honors) 1972
Outstanding Young Women in America, 1983
University of Florida Research Achievement Award, 1992
Best Doctors in America: Southeast Region, First Edition
Best Doctors in America, 4th, 10th Edition, 2003-2013 Editions
How to Find the Best Doctors: Florida 2000
Who's Who in Medicine and Healthcare, 1st Edition, 5th-8th Edition
Who's Who of American Women, 16th-17th, 19th-21st, Millennium, 23rd-26th Editions, 28th Edition
Who's Who in America, 48th-53rd, 59th-60th, 63rd-68th Editions
Who's Who in the South and Southwest, Millennium Edition, 28th-33rd Edition
Who's Who in American Education, 6th-8th Editions
Guide to America's Top Pediatricians, 2002-2003, 2004-2005, 2008-2009, 2010
Who's Who in Science and Engineering, 11th Edition
UFRF Professorship 2007-2010
Lifetime Achievement Award, University of Florida College of Medicine, 2015

BOARDS: American Board of Pediatrics, written exam, 1980
American Board of Pediatrics, oral exam, 1981
Advanced Cardiac Life Support, 1982
Perinatology Board Certified, 1983
NRP, 2012

LICENSURE: Flex Exam, 1978
State of Georgia, 1978 #019814
State of Florida, 1979 #33753

SOCIETY
MEMBERSHIPS: Alachua County Medical Society, 1981-2002
Florida Medical Association, 1985-2002, 2008-2013
Committee on Substance Abuse, Council on Medical
Economics, 1989-92
American Academy of Pediatrics, 1981-present
Section on Perinatal Pediatrics, 1983-2013
Committee on Substance Abuse, 2003-2009
Florida Pediatric Society, 1981-2013
Chair, Committee on Substance Abuse, 1989-95
International Society for Infant Studies, 1989-2009
Southern Society for Pediatric Research, 1986-2013
Society for Pediatric Research, 1996-present
Society for Research in Child Development, 1999-2013
American Pediatric Society, 2003-present
Neurobehavioral Teratology Society, 2005-present

GRANTS/RESEARCH
SUPPORT AWARDS: Division of Sponsored Research - Graduate Research Assistantship
Program, Co-Principal Investigator, \$4,780.32, 1985.

National Center for Nursing Research, NIH, "Self-Regulatory
Gavage/Bottle Feeding of Preterm Infants," Co-Investigator,
1R01NR01206, \$308,025, January, 1985 - January, 1988.

Division of Sponsored Research. NIH Travel Funds Program. Co-
Principal Investigator, \$1,195, 1989.

Division of Sponsored Research. Graduate Research Assistantship
Program, Co-Principal Investigator, \$4,731.86, 1990.

Division of Sponsored Research. NIH Travel Funds Program. Co-
Principal Investigator, \$1200.00, 1990.

Division of Sponsored Research. NIH Travel Funds Program. Principal
Investigator, \$2,595.68, 1993.

National Center for Nursing Research, NIH, "Self-Regulatory
Newborn Care and Extrauterine Adaptation," Co-investigator,
1R01NR02444, \$902,734, February, 1991 - January, 1994.

National Institute on Drug Abuse, NIH, "Project CARE (Cocaine
Abuse in the Rural Environment)," Co-Principal Investigator,
1R01DA05854, \$1,774,981. February, 1991 - January, 1996.

Division of Sponsored Research. Graduate Research Assistantship
Program, Co-Principal Investigator, \$ 6,002.49, 1992.

Center for Substance Abuse Treatment, "Evaluation of Services
Grant Program for Residential Treatment for Pregnant and
Postpartum Women, Their Infants, and Siblings," Co-Investigator,

\$740,843.30, October, 1993 - September, 1998.

Children's Miracle Network Telethon, "Project CARE,"
Co-Principal Investigator, \$17,600, January 1, 1994-
December 31, 1994.

National Institute on Drug Abuse, NIH, "Fetal Cocaine Metabolism
and Immunopharmacologic Effects," Co-Principal Investigator,
1R01DA08926, \$212,324, September, 1994 - August, 1995.

Division of Sponsored Research. Graduate Research Assistantship
Program, Co-Principal Investigator, \$6,527.40, 1995.

Division of Sponsored Research. Graduate Research Assistantship
Program, Co-Principal Investigator, \$6,128.53, 1995.

National Institute on Drug Abuse, NIH, "Project CARE,"
Co-Principal Investigator, 2R01DA05854, \$2,764,637,
July 1, 1996 - August 31, 2001.

National Institute on Drug Abuse, NIH, "Project CARE, Long-term
Minority Investigator Research Supplement," Co-Principal Investigator,
3R01DA05854-09S1, \$111,556, August 1, 1999-July 31, 2001.

National Institute on Drug Abuse, NIH, "Project CARE, Graduate
Student Minority Investigator Research Supplement," Co-Principal
Investigator, 3R01DA05854-09S2, \$27,850, August 1, 2000-July 31,
2001.

National Institute on Drug Abuse, NIH, "Project CARE, Neuroimaging
Administrative Supplement," Co-Principal Investigator, 3R01DA05854-
10S1, \$222,678, September 1, 2000-August 31, 2001.

National Institute on Drug Abuse, NIH, "Project CARE", Co-Principal
Investigator, 2R01DA05854, \$3,515,777, March 15, 2002-February 28,
2007.

National Institute on Children and Health Disorders, NIH, "Training in
Treatment Outcome Research for Children", Affiliate faculty member,
T32 HD07524, \$880,000, 2003-2008.

National Institute on Drug Abuse, NIH, "Project CARE", Co-Principal
Investigator, 3R01DA05854-16S1, \$78,266, October 1, 2007-February
28, 2008.

University of Florida, Opportunity Incentive Seed Fund, Co-Principal
Investigator, Project CARE: Brain Development and Behavior in
Adolescents, \$83,276, July 1, 2007-June 30, 2008.

National Institute on Drug Abuse, NIH, "Brain Development, Behavior
and Cognition in Pre- and Postnatal Cocaine Exposure", Site Co-Principal
Investigator, R21DA027561-01, \$934,862, September 15, 2009-
September 14, 2013.

PUBLICATIONS

BOOKS

Contributor of Chapters

1. **Behnke M**, Nackashi JA, Raulerson MD, Schuler PM, Mehta P: The pediatrician and the dying child. In: Wass, H.; Corr, C.A. (eds): Childhood and Death. New York: Hemisphere, pp 69-93, 1984.
2. **Behnke M**: Pulmonary assessment of pediatric patients. In: Eitzman DV, Koff P, Kopotic R, Neu J (eds): Neonatal and Pediatric Respiratory Care. St. Louis: C.V. Mosby, pp 26-43, 1988.
3. Anderson GC, **Behnke M**, Gill NE, Conlon M, Measel CP, McDonie TE: Self-regulatory gavage-to-bottle feeding for preterm infants: Effects on behavioral state, energy expenditure, and weight gain. In: Funk SG, Tornquist EM, Champagne MT, Copp LA, Wiese RA (eds): Key Aspect of Recovery: Improving Nutrition, Rest, and Mobility. New York: Springer, pp 83-97, 1990.
4. **Behnke M**, Koff PB: Patient Assessment. In: Koff PB, Eitzman DV, Neu J (eds): Neonatal and Pediatric Respiratory Care, 2nd ed. St. Louis: C.V. Mosby, pp 31-52, 1993.
5. Woods NS, **Behnke M**, Eyler FD, Conlon M, Wobie K: Cocaine use among pregnant women: Socioeconomic, obstetrical, and psychological issues. In: Lewis M, Bendersky M (eds): Mothers, Babies, and Cocaine: The Role of Toxins in Development. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., pp 305 - 332, 1995.

REFEREED PUBLICATIONS

1. Neimeyer GJ, **Behnke M**, Reiss J: Constructs and coping: Physicians' responses to patient death. Death Education 7(2):245-264, 1983.
2. **Behnke M**, Setzer E, Mehta P: Death counseling and psycho-social support by physicians concerning dying children. J Med Educ 59(11):906-908, 1984.
3. Hardt N, Kostenbauder M, Ogburn M, **Behnke M**, Resnick M, Cruz A: Influence of chorioamnionitis on long-term prognosis in low birthweight infants. Obstet & Gynecol 65(1):5-10, 1985.
4. Swingle H, **Behnke M**, Bucciarelli RL: Acquired arteriovenous malformation resulting from greater saphenous vein venipuncture. Clin Pediatr 24(2):88, 1985.
5. **Behnke M**, Reiss J, Neimeyer G, Setzer E: Grief Responses of pediatric house officers to a patient's death. Death Studies 11:169-176, 1987.
6. **Behnke M**, Carter RS, Hardt N, Eyler FD, Cruz A, Resnick MB: The relationship of Apgar scores, gestational age, and birthweight to survival of low-birthweight infants. Am J Perinatol 4:121-124, 1987.
7. Cruz AC, Frentzen BH, **Behnke M**: Hepatitis B: A case for prenatal screening of all patients. Am J Obstet Gynecol 156(5):1180-1183, 1987.
8. Gill NE, **Behnke M**, Conlon M, McNeely JB, Anderson GC: Effect of nonnutritive sucking on behavioral state in preterm infants before feeding. Nurs Res 37:347-350, 1988.
9. **Behnke M**, Eyler FD, Carter RL, Hardt NS, Cruz AC, Resnick MB: Predictive value of Apgar scores for developmental outcome in premature infants. Am J Perinatol 6:18-21, 1989.

10. Adams C, Eyler FD, **Behnke M**: Nursing intervention with mothers who are substance abusers. J Perinat Neonatal Nurs 3:43-52, 1990.
11. Gill NE, **Behnke M**, Conlon M, Anderson GC: Nonnutritive sucking modulates behavioral state for preterm infants before feeding. Scand J Caring Sci 6(1):3-7, 1992.
12. Woods NS, Eyler FD, **Behnke M**, Conlon M: Cocaine use during pregnancy: Maternal depressive symptoms and infant neurobehavior over the first month. Infant Behav Dev 16:83-98, 1993.
13. **Behnke M**, Eyler FD, Conlon M, Woods NS, Thomas V: The relationship between umbilical cord and infant blood gases and developmental outcome in very low birth weight infants. Clin Obstet Gynecol 36:73-81, 1993.
14. **Behnke M**, Eyler FD: The consequences of prenatal substance use for the developing fetus, newborn, and young child. Int J Add 28:1341-1391, 1993.
15. Lombardero N, Casanova O, **Behnke M**, Eyler FD, Bertholf RL: Measurement of cocaine and metabolites in urine, meconium, and diapers by gas chromatography/mass spectrometry. Ann Clin Lab Sci 23(5):385-394, 1993.
16. Meetze WH, Palazzolo V, Bowling D, **Behnke M**, Burchfield DJ, Neu J: Meconium passage in the micropremie: Effect of hypocaloric enteral priming. JPEN 17:537-540, 1993.
17. Eyler FD, **Behnke M**, Conlon M, Woods NS, Frentzen B: Prenatal cocaine use: A comparison of neonates matched on maternal risk factors. Neurotoxicol Teratol 16:81-87, 1994.
18. **Behnke M**, Eyler FD: Issues in prenatal cocaine use research: Problems in identifying users and an appropriate comparison group. Infant Mental Health J 15:146-157, 1994.
19. Casanova OQ, Lombardero N, **Behnke M**, Eyler FD, Conlon M, Bertholf RL: Detection of cocaine exposure in the neonate: Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med 118:988-993, 1994.
20. **Behnke M**, Eyler FD, Conlon M, Woods NS, Casanova OQ: Multiple risk factors do not identify cocaine use in rural obstetrical patients. Neurotoxicol Teratol 16:479-484, 1994.
21. Worthington-White DA, **Behnke M**, Gross S: Premature infants require additional folate and vitamin B-12 to reduce the severity of the anemia of prematurity. Am J Clin Nutr 60:930-935, 1994.
22. Carter RL, **Behnke M**, Ariet M, Dickman H, Resnick MB: An index for early assessment of neonatal survival in low birthweight infants: An alternative to Apgar scores. Am J Perinatol 12:392-395, 1995.
23. Eyler FD, **Behnke M**: Prenatal cocaine exposure: Consequences for child and family. J Fla Med Assoc 82:603-606, 1995.
24. **Behnke M**, Eyler FD, Conlon M, Casanova OQ, Woods NS: How fetal cocaine exposure increases neonatal hospital costs. Pediatrics 99: 204-208, 1997.
25. Wineker RE, Goldberger BA, Tebbett IR, **Behnke M**, Eyler FD, Wobie K, Karlix J, Conlon M, and Bertholf R: Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J Analytical Toxicology 21: 97-104, 1997.
26. **Behnke M**, Eyler FD, Woods NS, Wobie K, Conlon M: Rural pregnant cocaine users: An in-depth sociodemographic comparison. J Drug Issues 27:501-524, 1997.

27. Wobie K, Eyler FD, Conlon M, Clarke L, **Behnke M**: Women and children in residential treatment: Outcomes for mothers and their infants. J Drug Issues 27:585-606, 1997.
28. Wobie K, Eyler FD, **Behnke M**, Conlon M: Symbolic expression of feelings and depressive symptoms in high-risk pregnant women. J Fla Med Assoc. 84:384-390, 1997.
29. Eyler FD, **Behnke M**, Conlon M, Woods NS, Wobie K: Birth outcome from a prospective matched study of prenatal crack/cocaine use. Part I: Interactive and dose effects on health and growth. Pediatrics 101:229-237, 1998.
30. Eyler, FD, **Behnke M**, Conlon M, Woods NS, Wobie K: Birth outcome from a prospective, matched study of prenatal crack/cocaine use. Part II: Interactive and dose effects on neurobehavioral assessment. Pediatrics 101:237-241, 1998.
31. **Behnke M**, Eyler FD, Conlon M, Wobie K, Woods NS, Cumming W: Incidence and description of structural brain abnormalities in cocaine-exposed newborns. J Pediatrics 132:291-294, 1998.
32. Woods NS, Eyler FD, Conlon M, **Behnke M**, Wobie K: Pygmalion in the cradle: Observer bias against cocaine-exposed infants. J Dev Behav Pediatr 19:283-285,1998.
33. Karlix JL, **Behnke M**, Eyler FD, Wobie K, Adams V, Freiburger B, Conlon M, Tebbett IR: Perinatal cocaine suppresses the fetal immune system. Pediatr Res 44:43-46, 1998.
34. **Behnke M**, Eyler FD, Garvan CW, Tenholder M, Wobie K, Woods NS, Conlon M, Cumming W: Cranial ultrasound abnormalities identified at birth: Their relationship to perinatal risk and neurobehavioral outcome. Pediatrics 103:e41, 1999.
35. Eyler FD, **Behnke M**: Early development of infants exposed to drugs prenatally. Clinics Perinatol 26:107-150, 1999.
36. Eyler FD, **Behnke M**, Woods NS, Wobie K: Examiner masking in research on the effects of prenatal cocaine exposure. J Drug Issues 29:215-224, 1999.
37. **Behnke M**, Eyler FD, Garvan CW, Wobie K: The search for congenital malformations in newborns with fetal cocaine exposure. Pediatrics 107:e74, 2001.
38. Winecker RE, Goldberger BA, Tebbett IR, **Behnke M**, Eyler FD, Karlix JL, Wobie K, Conlon M, Phillips D, Bertholf R: Detection of cocaine and its metabolites in breast milk. J Forensic Sci 46:1221-1223, 2001.
39. Eyler FD, **Behnke M**, Garvan C, Woods NS, Wobie K, Conlon M: Neonatal evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicol Teratol 23:399-411, 2001.
40. **Behnke M**, Eyler FD, Garvan CW, Wobie K, Hou W: Cocaine exposure and developmental outcome from birth to six months. Neurotoxicol Teratol 24:283-295, 2002.
41. Saxonhouse MA, **Behnke M**, Williams JL, Richards D, Weiss MD: Mucopolysaccharidosis type VII presenting with isolated neonatal ascites. J Perinatol 23:73-75, 2003.
42. Wobie K, Eyler FD, Garvan CG, Hou W, **Behnke M**: Prenatal cocaine exposure: An examination of mother/infant separation during the first year of life. J Drug Issues 34:77-94, 2004.

43. Hou W, Wang Z, Garvan CW, **Behnke M**, Eyler FD, Wu R: A generalized model for detecting genetic determinants underlying longitudinal traits with unequally spaced measurements and time-dependent correlated errors. BioStatistics 6:420-433, 2005.
44. Eyler FD, **Behnke M**, Garvan CW, Wobie K, Tebbett I: Relative ability of biologic specimens and interviews to detect prenatal cocaine use. Neurotoxicol Teratol 27:677-687, 2005.
45. **Behnke M**, Eyler FD, Warner TD, Garvan CW, Hou W, Wobie K: Outcome from a prospective, longitudinal study of prenatal cocaine use: Preschool development at three years of age. J Pediatr Psychol 31:41-49, 2006.
46. Dow-Edwards DL, Benveniste H, **Behnke M**, Bandstra ES, Singer LT, Hurd YL, Stanford LR: Neuroimaging of prenatal drug exposure. Neurotoxicol Teratol 28:386-402, 2006.
47. Warner TD, **Behnke M**, Eyler FD, Garvan CW, Hou W, Wobie K: Predicting caregiver reported behavior problems in cocaine-exposed children at 3 years. J Behav Dev Pediatr 27:83-92, 2006.
48. Warner TD, **Behnke M**, Eyler FD, Padgett K, Leonard CM, Hou W, Garvan CW, Schmalfuss IM, Blackband SJ: Diffusion Tensor Imaging of Frontal White Matter and Executive Functioning in Cocaine-Exposed Children Pediatrics 118:2014-2024, 2006.
49. Hou W, Garvan CW, Littell RC, **Behnke M**, Eyler FD, Wu R: A framework to monitor environment-induced major genes for developmental trajectories: Implication for a prenatal cocaine exposure study. Statistics in Medicine 25:4020-4035, 2006.
50. Eyler FD, Warner, TD, **Behnke M**, Hou W, Wobie K, Garvan CW: Executive Functioning at Ages 5 and 7 in Children with Prenatal Cocaine Exposure. Dev Neurosci 31:121-136, 2009.
51. Warner TD, **Behnke M**, Eyler FD, Szabo N, Algina J: Early Adolescent Cocaine Use as Determined by Hair Analysis in a Prenatal Cocaine Exposure Cohort. Neurotoxicol Teratol 33:88-99, 2011.
52. Roussotte F, Soderberg L, Warner T, Narr K, Lebel C, **Behnke M**, Eyler F, Sowell E: Adolescents with Prenatal Cocaine Exposure Show Subtle Alterations in Striatal Surface Morphology and Frontal Cortical Volumes. J Neurodev Disorders 4:1-10, 2012.
53. Lebel C, Warner T, Colby J, Soderberg L, Roussotte F, **Behnke M**, Eyler FD, Sowell ER: White Matter Microstructure Abnormalities and Executive Function in Adolescents with Prenatal Cocaine Exposure. Psychiatry Research: Neuroimaging 213:161-68, 2013.
doi.org/10.1016/j.psychres.2013.04.002 (PMID:23769420)
54. Warner T, Roussos-Ross D, **Behnke M**: It's Not Your Mother's Marijuana: Effects on Maternal-Fetal Health and the Developing Child. Clinics Perinatol 41:877-894, 2014.
[doi:10.1016/j.clp.2014.08.009](https://doi.org/10.1016/j.clp.2014.08.009)

REFEREED ABSTRACTS-PRESENTED

1. Behnke M, Mehta P: Lack of physician training and involvement in psychosocial support related to death and dying in childhood. American Cancer Society Research Seminar, University of South Florida, February 14, page 12A, 1981.
2. Behnke M, Mehta P: Death counseling as it relates to adequate psychosocial support by the physician for the dying child and family. Pediatr Res 15(4):551A, 1981.

3. Behnke M, Neimeyer GJ, Reiss J, Setzer ES: Psychophysiologic and behavioral effects of patient death on pediatric house officers. Pediatr Res 16(4):183A, 1982.
4. Hardt N, Behnke M, Eyler F, Resnick M, Cruz A: Apgar score and development at one year: Lack of association in 151 very low birthweight infants (VLBWI). Society of Perinatal Obstetricians, 1983.
5. Gill NE, Behnke M, McNeely JB, Worth AM: Nonnutritive sucking (NNS) and state modulation for preterm infants before feeding. Infant Behav Dev 9:140A, 1986.
6. Anderson GC, Behnke M, Worth AM, McNeely JB, Gill NE, Griggs CC: Self-regulatory gavage to bottle feeding of pre-term infants: A new method. International Nursing Research Conference, Alberta, Canada, page 48, 1986.
7. Behnke M, Eyler FD: Usefulness of clinical assessments of asphyxia to predict developmental status in very low birthweight infants (VLBWI). Infant Behav Dev 11:22A, 1988.
8. Behnke M, Gill N, Conlon M, Anderson GC: Determining optimal behavioral states for feeding premature infants. Infant Behav Dev 11:23A, 1988.
9. Gill NE, Behnke M, Conlon M, Anderson GC: Nonnutritive sucking: Effect on behavioral state in preterm infants prefeeding. National Symposium of Nursing Research. San Francisco, CA, page 85, September, 1988.
10. Gill NE, Measel CP, Behnke M, Anderson GC: Preterm infant weight at first bottle: Relation to days to 100% bottle feeding. Fourth Open Conference of the Work Group of European Nurse-Researchers. Jerusalem, Israel, page 62, June, 1988.
11. Behnke M, Eyler FD, Nackashi JA, Conlon M: Relationship of cord gas and first arterial blood gas measures to developmental status in very low birthweight infants (VLBWI). Pediatr Res 22(4):441A, 1988.
12. Eyler FD, Behnke M: Issues in identification and follow-up of cocaine-exposed neonates. Society for Research in Child Development Abstracts 6:138, 1989.
13. Behnke M, Eyler FD, Conlon M, Adams C, Stewart NJ: Cocaine exposure and perinatal complications in well-born and intensive care (ICU) neonates. Infant Behav Dev 13:267A, 1990.
14. Stewart NJ, Eyler FD, Behnke M, Conlon M: Neonatal behavior in cocaine-exposed infants and maternal depression. Infant Behav Dev 13:631A, 1990.
15. Eyler FD, Behnke M, Conlon M, Stewart N, Frentzen B, Cruz A: Perinatal outcome of cocaine-using mothers compared to controls matched on prenatal risk factors. Pediatr Res 27(4):1440A, 1990.
16. Casanova O, Behnke M, Eyler FD, Conlon M, Stewart N, Adams C: Comparison of cocaine users versus non-users in high-risk obstetrical patients presenting to labor and delivery. Clin Res 38(4):967A, 1990.
17. Behnke M, Eyler FD: Issues in perinatal cocaine abuse research: The interface between medicine and child development. Society for Research in Child Development Abstracts 8:5, 1991.

18. Woods NS, Eyler FD, Behnke M, Conlon M: Cocaine use during pregnancy: Maternal depressive symptoms and neonatal neurobehavior over the first month. Society for Research in Child Development Abstracts 8:505, 1991.
19. Casanova OQ, Behnke M, Eyler FD, Woods NS: Cost analysis of cocaine-exposed infants compared to controls matched on prenatal risk factors. Pediatr Res 29(4):252A, 1991.
20. Woods NS, Eyler FD, Behnke M, Conlon M: Cocaine use during pregnancy: Maternal depressive symptoms and neonatal neurobehavior over the first month. Pediatr Res 29(4):271A, 1991.
21. Eyler FD, Woods NS, Behnke M, Conlon M: Changes over a decade: Adult-infant interaction in the NICU. Pediatr Res 29(4):255A, 1991.
22. Woods NS, Conlon M, Eyler FD, Behnke M: The Caregiving Effort and Satisfaction Scales (CESS): A pilot study with cocaine-using mothers. Infant Behav Dev 15:774A, 1992.
23. Eyler FD, Woods NS, Behnke M, Conlon M: Adult-infant interaction in the NICU: Has it changed and is health status important? Infant Behav Dev 15:401A, 1992.
24. Lombardero-Tuttle N, Casanova O, Behnke M, Eyler FD, Bertholf RL: Comparison of specimens for GC/MS detection of prenatal cocaine exposure. Clin Chem 38:960A, 1992.
25. Wobie K, Eyler FD, Conlon M, Behnke M, Woods NS: Symbolic expression of feelings and depressive symptoms in high-risk mothers. Society for Research in Child Development Abstracts 9:658, 1993.
26. Eyler FD, Woods NS, Conlon M, Wobie K, Behnke M, Anderson C, Maag L: Pygmalion in the cradle: Observer bias against cocaine-exposed infants. Pediatr Res 35(4):112A, 1994.
27. Eyler FD, Behnke M, Conlon M, Woods NS, Wobie K: Birth outcome from a longitudinal study of prenatally matched cocaine-using and non-using women. Pediatr Res 35(4):268A, 1994.
28. Behnke M, Eyler FD, Conlon M, Woods N, Wobie K: Relationship of cranial ultrasound (CUS) findings to perinatal risk and neurobehavioral outcome in cocaine-exposed newborns. Pediatr Res 37(4):250A, 1995.
29. Eyler FD, Behnke M, Conlon M, Woods N, Wobie K: A controlled evaluation of neonatal cocaine [withdrawal]. Neurobehavioral effects over the first week. Pediatr Res 37(4):255A, 1995.
30. Anderson GC, Chang HP, Behnke M, Eyler FD, Conlon M: Self-regulatory mothering (SR) postbirth: Effects on, and correlation between, infant crying and salivary cortisol. Pediatr Res 37(4):12A, 1995.
31. Woods NS, Eyler FD, Behnke M, Conlon M, Wobie K, Peterson KM: Cocaine-exposed neonates and their mothers: Patterns of interaction during feeding. Infant Behav Dev 19:828A, 1996.
32. Behnke M, Eyler FD, Conlon M, Woods NS, Wobie K: A longitudinal study of prenatal cocaine exposure: 6-month outcome. Infant Behav Dev 19:324A, 1996.
33. Eyler FD, Behnke M, Conlon M, Woods NS, Wobie K: A longitudinal study of prenatally cocaine-exposed infants and matched controls: Relationship of one month blinded Brazelton assessments (BNBAS) and HOME scores. Infant Behav Dev 19:444A, 1996.

34. Maag L, Eyler FD, Woods NS, Behnke M, Wobie K, Conlon M: Adult bias regarding cocaine-exposed children. Sixth Florida Conference on Child Health Psychology, Gainesville, FL, April, 1997.
35. Holler K, Eyler FD, Behnke M, Conlon M, Fennell EB, Maag L, Wobie K, Woods NS: Behavioral outcome at age 3 for children prenatally exposed to crack cocaine. J Intl Neuropsychology Society 3(1), 1997.
36. Behnke M, Eyler FD, Conlon M, Wobie K, Woods NS: Longitudinal growth patterns in cocaine-exposed children. Pediatr Res 41(4):191A, 1997.
37. Eyler FD, Tebbett IR, Behnke M, Wobie K, Conlon M, Karlix J: Relative efficacy of biologic specimens and interviews in detection of prenatal cocaine use. Pediatr Res 41(4):193A, 1997.
38. Behnke M, Eyler FD, Garvan CW, Wobie K, Conlon M, Woods NS, Cumming W: Minor cranial ultrasound abnormalities at birth and their relationship to neurobehavioral outcome: A prospective, longitudinal study of high-risk newborns. Infant Behav Dev 21:286A, 1998.
39. Maag L, Eyler FD, Woods NS, Behnke M, Franks B, Garvan CW, Conlon M: ☐Cocaine-exposed☐children: Is the label itself a risk factor? Infant Behav Dev 21:245A, 1998.
40. Garvan CW, Eyler FD, Behnke M, Conlon M, Wobie K, Marron J: Modeling neonatal head circumference percentile: Results from a prospective study examining effects of prenatal cocaine use. Infant Behav Dev 21:425A, 1998.
41. Eyler FD, Behnke M, Wobie K, Woods NS, Conlon M: Examiner masking in research on the effects of prenatal cocaine exposure. Infant Behav Dev 21:10A, 1998.
42. Eyler FD, Behnke M, Garvan CW, Wobie K, Woods NS: Newborn behavioral effect of cocaine: Is it amount of prenatal exposure or acute toxicity? Pediatr Res 43(4):1234A, 1998.
43. Wobie K, Eyler FD, Behnke M, Garvan CW: To have and to hold: A descriptive study of custody status following prenatal exposure to cocaine. Pediatr Res 43(4):1370A, 1998.
44. Sinha I, Behnke M, Eyler FD, Garvan CW, Wobie K: Cocaine-exposed children in foster/kinship care: Effects on longitudinal growth patterns. Pediatr Res 43(4):1338A, 1998.
45. Behnke M, Eyler FD, Garvan CW, Wobie K, Conlon M: Congenital abnormalities in newborns with fetal cocaine exposure. Pediatr Res 43(4):361A, 1998.
46. Garvan CW, Eyler FD, Behnke M, Wobie K, Marron, JV: Measuring patterns of substance use among pregnant women. Seventh Biennial Symposium on Statistical Methods, Atlanta, GA, January, 1999.
47. Maag L, Eyler FD, Behnke M, Wobie K, Garvan C: Language skills in a naturalistic setting: Results from a study of prenatal cocaine exposure. Society for Research in Child Development Abstracts, 1999.
48. Behnke M, Eyler FD, Garvan CW, Wobie K, Marron J: The relationship of outcome to commonly used quantitative assessments of prenatal cocaine use. Pediatr Res 45(4):1394A, 1999.
49. Wobie K, Eyler FD, Behnke M, Garvan CW: Mother/infant separation: Outcomes and placement status of children prenatally exposed to cocaine. Proceedings from the Third Meeting of the National Leaders in Women's Health, 1999.

50. Eyler FD, Behnke M, Wobie K, Garvan CW: Prenatal cocaine exposure: A longitudinal assessment of behavior from birth to age 3. Pediatr Res 47(4):1819A, 2000.
51. Eyler FD, Behnke M: State of the art: A melding of teratogenic and transactional models in research on prenatal cocaine exposure. International Conference on Infant Studies, Brighton, England, July, 2000.
52. Behnke M, Eyler FD: An example of transactional analyses in a longitudinal, developmental study of prenatal cocaine use. International Conference on Infant Studies, Brighton, England, July, 2000.
53. Garvan CW, Behnke M, Eyler FD: Examining substance use data during pregnancy with projection pursuit methodology. International Conference on Infant Studies, Brighton, England, July, 2000.
54. Wobie K, Behnke M, Eyler FD, Garvan CW: Accessing and assessing the caregiver: Who, what, when, where, why, and how. International Conference on Infant Studies, Brighton, England, July, 2000.
55. Sinha I, Behnke M, Eyler FD, Garvan CW, Wobie K: Cocaine-exposed infants in out-of-home placement: Effects on longitudinal growth patterns. American Academy of Pediatrics, October, 2000.
56. McNeilly L, Eyler FD, Behnke M, Garvan CW, Wobie K: Language development in children birth to three with prenatal cocaine exposure. American Speech-Language Hearing Association, Washington, D.C., November 18, 2000.
57. Byrd D, Sweeney K, Berg WK, Eyler FD, Behnke M, Wobie K: Effects of prenatal cocaine exposure and SES on the performance of 7-year-olds on a frontal lobe sensitive task. Arch Clin Neuropsych 15(8):799-800, 2000.
58. Eyler FD, Behnke M, Garvan CW, Wobie K, Edwards CD: Cocaine exposure and developmental outcome birth to three. Pediatr Res 49(4):319A, 2001.
59. McNeilly L, Eyler FD, Behnke M: Linguistic development and environment in young children with poly-drug exposure. Florida Association of Speech Language Pathologists and Audiologists, Orlando, FL, May, 2001.
60. McNeilly L, Eyler FD, Behnke M: Longitudinal assessment of children with prenatal cocaine exposure (0-5). American Speech-Language Hearing Association, New Orleans, LA, November, 2001.
61. Eyler FD, Behnke M, Garvan CW, Wobie K, Hou W: Prenatal cocaine exposure: Analysis of direct and indirect effects on 36-month developmental outcome. International Conference on Infant Studies, Toronto, Canada, April, 2002.
62. McNeilly LG, Eyler FD, Behnke M, Garvan CW: Longitudinal assessment of language in children with prenatal cocaine exposure: Birth to 5 years. International Conference on Infant Studies, Toronto, Canada, April, 2002.
63. Behnke M, Eyler FD, Garvan CW, Wobie K, Hou W: Five-year outcome from a prospective, matched study of prenatal cocaine exposure (PCE). Pediatr Res 51(4):359A, 2002.
64. Garvan CW, Behnke M, Conlon M, Hou W, Eyler FD: Asymmetric head growth and prenatal cocaine use: Results from a matched control study. Pediatr Res 51(4):358A, 2002.

65. Edwards CDA, Eyler FD, Behnke M: A multidimensional approach to the study of prenatal cocaine exposure (PCE): Integrating biomedical, behavioral, and sociological perspectives. Pediatr Res 51(4):359A, 2002.
66. Warner TD, Eyler FD, Behnke M, Fennel E, Dede D: Long term effects of prenatal cocaine exposure on children's attention and reading abilities. National Academy of Neuropsychology, Miami, FL, October, 2002.
67. Eyler FD, Behnke M, Garvan CW, Wobie K, Hou W: Analysis of the direct and indirect effects of prenatal cocaine exposure on 36-month developmental outcome. National Academy of Neuropsychology, Miami, FL, October, 2002.
68. Eyler FD, Behnke M, Garvan CW, Wobie K, Warner TD, Hou W: Effects of prenatal cocaine exposure and other risk factors on outcome in a prospectively enrolled matched cohort now entering school. Society for Research in Child Development Abstracts, 2003.
69. Garvan CW, Hou W, Behnke M, Eyler FD: A comparison of imputation strategies for estimating cocaine use during pregnancy. Ninth Biennial Symposium on Statistical Methods, Atlanta, GA, January, 2003.
70. Warner T, Eyler FD, Behnke M, Garvan CW, Hou W: Predicting behavior problems at 3 years in children with prenatal cocaine exposure: Structural equation modeling with a prospectively enrolled sample. International Conference on Infant Studies, Chicago, IL, May, 2004.
71. Behnke M, Eyler FD, Garvan CW, Hou W, Wobie K, Warner TD: Effects of prenatal cocaine exposure on intelligence (IQ) in a longitudinal cohort of 5-7 year olds. Pediatr Res 55(4):492A, 2004.
72. Warner TD, Eyler FD, Behnke M, Garvan CW, Hou W, Fennell EB: Effects of prenatal cocaine exposure on attention and reading: Structural equation modeling using a prospectively enrolled sample. Pediatr Res 55(4):493A, 2004.
73. Padgett KR, Eyler FD, Behnke M, Leonard CM, Crandall KM, Mareci TH, Black TA, Schmalfluss IM, Garvan CW, Blackband SJ: Reduction of fractional anisotropy in frontal white matter in prenatally cocaine exposed children. International Society for Magnetic Resonance in Medicine, Kyoto, Japan, May 15-21, 2004.
74. Tatarchuk YL, Leonard CM, Gentry EH, Padgett KR, Eyler FD, Behnke M: Evaluating pars triangularis morphology in a population of children prenatally exposed to cocaine. 20th Annual South East Nerve Net, Decatur, GA, March, 2004.
75. Pyko M, Eyler FD, Behnke M, Garvan CW, Leonard CM: Investigation of the cingulate sulcus in children prenatally exposed to cocaine. 20th Annual South East Nerve Net, Decatur, GA, March, 2004.
76. Crandall KM, Padgett KR, Leonard CM, Garvan CW, Schmalfluss IM, Blackband SJ, Eyler FD, Behnke M: Investigating white matter changes in children prenatally exposed to cocaine using diffusion tensor imaging. 20th Annual South East Nerve Net, Decatur, GA, March, 2004.
77. Tatarchuk KL, Eyler FD, Behnke M, Garvan CW, Welch A, Schmalfluss I, Warner TD, Hou W, Komaragiri V, Leonard CM: Evaluating brain morphology in a sample of children prenatally exposed to cocaine. Society for Neuroscience, San Diego, CA, October, 2004.
78. Crandall KM, Padgett KR, Leonard CM, Garvan CW, Schmalfluss IM, Blackband SJ, Eyler FD, Behnke M: Investigating white matter changes in children prenatally exposed to cocaine using diffusion tensor imaging. Society for Neuroscience, San Diego, CA, October, 2004.

79. Eyler FD, Behnke M, Warner TD, Hou W, Wilson CG: Cocaine exposure at ages 5 and 7. Society for Research in Child Development Abstracts, 2005.
80. Warner TD, Eyler FD, Behnke M, Hou W, Garvan CW: Normative data for low SES African-American children on selected Halstead-Reitan tests. International Neuropsychological Society, 2005.
81. Padgett KR, Garvan CW, Crandall KM, Black TA, Eyler FD, Behnke M, Leonard CM, Schmalfluss IM, Blackband SJ: A comparison of two techniques for white matter segmentation in a clinical DTI study. International Society for Magnetic Resonance in Medicine, 2005.
82. Padgett KR, Behnke M, Eyler FD, Leonard CM, Crandall KM, Schmalfluss IM, Garvan CW, Warner TD, Blackband SJ: Diffusion changes in frontal white matter in prenatally cocaine exposed children. International Society for Magnetic Resonance in Medicine, 2005.
83. Sullivan SE, Behnke M, Garvan CW, Hou W, Wobie K, Eyler FD: Does age of initial out-of-home placement impact development of cocaine-exposed infants from birth to age three? Pediatric Academic Societies, 2005.
84. Warner TD, Eyler FD, Padgett K, Hou W, Garvan CW, Leonard C, Crandall K, Schmalfluss I, Blackband S, Behnke M: Diffusion tensor imaging (DTI) of frontal white matter development and executive functioning in prepubescent children with prenatal cocaine exposure (PCE). Pediatric Academic Societies, 2005.
85. Eyler FD, Behnke M, Szabo NJ, Garvan CW, Hou W, Wobie K: Cocaine ingestion in pre-adolescents in a prospective, longitudinal study of the effects of prenatal cocaine exposure. Society for Research on Adolescence, 2006.
86. Sullivan SE, Eyler FD, Hou W, Garvan C, Behnke, M: Kindergarten teacher reported behavior problems: Prenatal cocaine exposure, home placement, and gender effects. Pediatric Academic Societies, 2006.
87. Warner TD, Hou W, Eyler FD, Behnke M, Garvan CW: Longitudinal analysis of motor development in children with prenatal cocaine exposure. Pediatric Academic Societies, 2006.
88. Eyler FD, Warner TD, Hou W, Garvan CG, Behnke M: The effects of prenatal cocaine and quality of the environment on reports of depressive symptoms by 7 and 10.5 year olds. Society for Research in Child Development, 2007.
89. Warner TD, Behnke M, Hou W, Garvan CG, Eyler FD: Attention functioning of children with prenatal cocaine exposure on a visual and auditory continuous performance task. Society for Research in Child Development, 2007.
90. Behnke M, Eyler FD, Warner TD, Garvan CW, Hou W, Szabo N : Postnatal cocaine exposure and behavioral outcome in early adolescence. Pediatric Academic Societies, 2007.
91. Warner TD, Behnke M, Eyler FD, Algina J: Predictors of cocaine use in pre-adolescents enrolled in a prospective, longitudinal study of effects of prenatal cocaine exposure. Society for Research on Adolescence, 2008.
92. Warner TD, Eyler FD, Behnke M, Szabo NJ. Pre-adolescent cocaine use: relationship to prenatal exposure, caregiver problems and cognitive/behavior problems. Pediatric Academic Societies, 2008.

93. Warner TD, Eyler FD, Behnke M. Effects of prenatal cocaine exposure, caregiver attachment, and exposure to violence on mental health problems in pre-adolescents. *Pediatric Academic Societies*, 2008
94. McCann SJ, Warner TD, DeLuca TL, Behnke M, Berg WK, Eyler FD: Results from a prospective, longitudinal study of prenatal cocaine exposure: Executive functioning in school-age children. *Society for Research in Child Development*, 2009.
95. Eyler FD, Behnke M, Warner TD, Leite W, Algina J: Results from a prospective, longitudinal study of prenatal cocaine exposure: Precursors of pre-teen risky behavior and drug use. *Society for Research in Child Development*, 2009.
96. Warner TD, Behnke M, Eyler FD: No effect of prenatal cocaine exposure on the Wisconsin Card Sorting Test during early adolescence. *International Neuropsychological Society*, 2009.
97. Behnke M, Eyler FD, Warner TD, Leite WL, Algina J: Precursors of delinquency and drug use in youth with prenatal cocaine exposure (PCE). *Pediatric Academic Societies*, 2009.
98. Daniels L, Warner TD, Behnke M, Eyler FD: Executive functioning in adolescents with prenatal cocaine exposure: Performance on the Iowa Gambling Task. *Society for Research on Adolescence*, 2010.
99. McCann SJ, Warner TD, Heaton SC, Behnke M, Eyler FD: Latent growth curve (LGC) analysis of the development of working memory (WM) and set-shifting abilities in a prospective, longitudinal cohort of children with prenatal cocaine exposure (PCE). *International Neuropsychological Society*, 2010.
100. McCann SJ, Warner TD, Heaton SC, Eyler FD, Behnke M: Longitudinal development of executive functioning in a prospective cohort of children with prenatal cocaine exposure (PCE): Latent growth curve analysis. *Pediatric Academic Societies*, 2010.
101. Denney M, Hennessy S, Snyder P, Eyler FD, Behnke M: Early intervention preservice personnel preparation within a primary service provider approach. *Division for Early Childhood (DEC) International Conference*, 2010.
102. DeLuca TL, Warner TD, Behnke M, Eyler FD: Home environment as a predictor of academic skills in a cohort with prenatal cocaine exposure (PCE): A latent growth curve analysis. *Society for Research in Child Development*, 2011.
103. Warner TD, Behnke M, Eyler FD: Emotional regulation in adolescents with a history of cocaine use (CU) and prenatal cocaine exposure (PCE). *Pediatric Academic Societies*, 2011.
104. Daniels L, Warner TD, Behnke M, Eyler FD: Effects of prenatal cocaine exposure on executive functioning in early adolescence. *American Psychiatric Association*, 2011.
105. Roussotte F, Soderberg L, Warner T, Narr K, Lebel C, Behnke M, Eyler FD, Sowell E: Regional patterns and neuropsychological correlates of striatal morphology in adolescents with prenatal cocaine exposure. *Organization for Human Brain Mapping*, 2011.
106. Lebel C, Warner T, Roussotte F, Behnke M, Eyler F, Sowell E: Diffusion tensor imaging of adolescents with prenatal cocaine exposure. *Organization for Human Brain Mapping*, 2011.
107. Schmutz KM, Leonard CM, Warner TD, Behnke M, Eyler FD: Orbitofrontal sulcal structure, executive functioning, and prenatal cocaine exposure. *Society for Neuroscience*, 2011

108. Warner TD, Behnke M, Eyler FD: Executive function in early adolescence: effects of prenatal cocaine exposure (PCE). *Pediatric Academic Societies*, 2012.
109. Roussotte F, Warner T, Narr K, Lebel C, Behnke M, Eyler FD, Sowell E: Volumetric changes in frontal cortical regions in adolescents with prenatal cocaine exposure. *Organization for Human Brain mapping*, 2012.
110. Warner TD, Behnke M, Eyler FD: Prenatal drug exposure and self-reported drug use in adolescence: The role of psychological functioning. *Pediatric Academic Societies*, 2013.
111. Clark C, Warner TD, Algina J, Snyder P, Eyler FD, Behnke M: Home environment, family social support, and cognitive and motor development of infants and toddlers of mothers with multiple risks: Parallel process latent growth curve analysis. *Pediatric Academic Societies*, 2014.

NON-REFEREED ABSTRACTS-NOT PRESENTED

Eyler FD, Behnke M, Hardt N, Cruz A, Resnick MB: Developmental outcome of low birthweight infants (LBWI): Apgar score revisited. *Pediatr Res* 17(4):96A, 1983.

Behnke M, Eyler FD, Hardt N, Carter R, Cruz A, Resnick MB: Will my baby survive? A new method of prediction for low birthweight infants (LBWI). *Pediatr Res* 17(4):93A, 1983.

Behnke M, Setzer E, Ballinger W: Neuropathologic assessment and clinical correlates of choroid plexus hemorrhage (CPH) in a neonatal autopsy population. *Pediatr Res* 18(4):311A, 1984.

Riddell JP, Behnke M, Neu J, Baumgartner T, Gersovitz MT, Borum PR: L-Carnitine supplementation in very low birthweight premature infants receiving total parenteral nutrition. *Carnitine Symposium*, 1985.

Behnke M, Eyler FD, Carter RL, Resnick MB: Use of Apgar scores in a risk index to predict outcome in low birthweight (LBW) infants. *Pediatr Res* 20(4):374A, 1986.

Measel CP, Behnke M, Anderson GC: Postconceptional age (PCA) at first bottle: Relation to days until 100% bottle feeding. *Pediatr Res* 22(4):488A, 1988.

Eyler FD, Behnke M, Stewart NJ, Bucciarelli RL: Incidence and effects of cocaine use: Perinatal center experience. *Pediatr Res* 23(4):446A, 1988.

Thomas VJ, Behnke M, Eyler FD, Conlon M: A predictive model for neurodevelopmental outcome in preterm infants. *Pediatr Res* 25(4):265A, 1989.

Gill NE, Behnke M, Conlon M, Anderson GC: Relation between feeding performance and temperature in premature infants.

Behnke M, Eyler FD, Conlon M, Stewart N, Adams C: Relationship between perinatal complications and cocaine use in a high-risk obstetrical population. *Pediatr Res* 27(4):1420A, 1990.

Behnke M, Eyler FD, Kazimour K: Developmental outcome of children in foster care who were cocaine-exposed in utero. *Pediatr Res* 29(4):251A, 1991.

Casanova OQ, Lombardero-Tuttle N, Eyler FD, Bertholf R, Behnke M: Comparison of drug history to maternal urine, infant □ urine and meconium for prenatal cocaine exposure. Pediatr Res 31(4):243A, 1992.

Palazzolo V, Meetze W, Burchfield D, Behnke M, Neu J: Meconium passage in the micropremie: Effects of hypocaloric enteral priming. Pediatr Res 31(4):292A, 1992.

Syfrett EB, Anderson GC, Behnke M, Neu J: Early and virtually continuous kangaroo care for lower-risk preterm infants: Effect on temperature, breastfeeding, supplementation, and weight. Proceedings of the Biennial Conference of the Council of Nurse Researchers, American Nurses Association, Washington, DC, November, 1993a.

Syfrett EB, Anderson GC, Behnke M, Neu J: Kangaroo care for 34-36 week infants beginning in the delivery room: Four infants and what we have learned. Proceedings of the Eighth Annual Nursing Conference in Neonatology. Kangaroo Care: Changing Times and Emerging Trends. Brigham & Women □ Hospital, Boston, MA, June 1993b.

Anderson GC, Hudson SJ, Behnke M, Eyler FD, Conlon M., Lane AE, Chang H-P: Randomized controlled trial (RCT) with transitional newborn infants: Effect of tub bath on crying and temperature. Sigma Theta Tau Scientific Sessions, December, 1977.

Youngblade L, Eyler FD, Behnke M: Comparison of Medicaid utilization of cocaine-exposed and non-exposed children. Pediatr Res 55(4):381A, 2004.

Warner TD, Eyler FD, Behnke M: Predictors of delinquent behavior in pre-adolescents with prenatal cocaine exposure. Society for Research on Adolescence, 2008.

DeLucca TL, Warner TD, McCann SJ, Eyler FD, Behnke M, Berg WK: Problem Solving Skills of Preteens With Prenatal Cocaine Exposure: Computerized Tower of London Performance. Society for Research in Child Development, 2009.

AMERICAN ACADEMY OF PEDIATRICS-COMMITTEE ON SUBSTANCE ABUSE

1. Kulig JH and Committee on Substance Abuse: Tobacco, alcohol, and other drugs: The role of the pediatrician in prevention, identification, and management of substance abuse. Pediatrics 115:816-821, 2005.
2. Knight JR, Mears CJ, Committee on Substance Abuse, and Council on School Health: Testing for drugs of abuse in children and adolescents: Addendum—testing in schools and at home. Pediatrics 119:627-630, 2007.
3. Williams JF, Storck M, Committee on Substance Abuse, and Committee on Native American Child Health: Inhalant abuse. Pediatrics 119:1009-1017, 2007.
4. Mears CJ, Knight JR, Council on School Health, and Committee on Substance Abuse: The role of schools in combating illicit substance abuse. Pediatrics 120:1379-1384, 2007.
5. Kokotailo PK and Committee on Substance Abuse: Alcohol use by youth and adolescents: A pediatric concern. Pediatrics 125:1078-1087, 2010.
6. Behnke M, Smith VC, Committee on Substance Abuse and Committee on Fetus and Newborn: Prenatal Substance Abuse: Short- and Long-term Effects on the Exposed Fetus. Pediatrics 131:e1009-e1024, 2013.

OTHER

1. Physical Examination of the Infant. Videotape for Medical Students, 1981.
2. Circumcision - Parent Handout, 1984.

3. Housestaff orientation manual for Nursery Services, 1984-1990 (updated yearly),
4. Behnke M: A Florida neonatologist speaks out. Florida Perinatal Social Work Newsletter 1(1):8,1989.
5. Behnke M, Eyer FD: Substance exposed infants: Short and long-term impact. NAPSW Forum 24(2):8-11, 2004.

INVITED PRESENTATIONS

1. Jaundice Neonatal Update: Infants at High Risk. Daytona Beach, FL, October, 1983.
2. Current Issues in Neonatology of Significance to the Pediatrician. Seventeenth Annual Pediatric Postgraduate Education Pre-football Game Seminars. Gainesville, FL, September, 1984.
3. Resuscitation of the Newborn. Fall 1984 Family Practice Review. Lake Buena Vista Palace, October, 1984.
4. Management of Hyperbilirubinemia in the Term Neonate. Fall 1984 Family Practice Review. Lake Buena Vista Palace, October, 1984.
5. Nutrition Requirements of the Neonate. Neonatal Intensive Care Course. Gainesville, FL, April, 1985.
6. Management of the Infant with Bronchopulmonary Dysplasia. Eighteenth Annual Pediatric Postgraduate Education Pre-football Game Seminars. Gainesville, FL, September, 1985.
7. Withholding Nutrition - Panel Discussion. Bioethics: Reality and Clinical Practice Today. Gainesville, FL, May, 1987.
8. Substance Abuse During Pregnancy and Infant Outcome. Workshop. Parent Care, Inc., Fifth Annual Conference, Newport Beach, CA, September, 1988.
9. Effect of Prenatal Cocaine Exposure on the Infant. Sixth Biennial Conference for Pediatric Nurses, College of Nursing. Jacksonville, FL, October, 1988.
10. Prenatal Cocaine Use and the Fetus. North Central Florida Association of Neonatal Nurses. Gainesville, FL, February 2, 1989.
11. Florida Network Panel. Substance Abuse and Pregnancy: Innocent Addicts. St. Petersburg Beach, FL, February 12-14, 1989.
12. Cocaine Babies: Testimony before the Florida House of Representatives HRS Subcommittee on Health, Mental Health, and Substance Abuse. Tallahassee, FL, February 8, 1989.
13. Cocaine Babies. National Medical Association, Pediatric Sub-section, Orlando, FL, July 17, 1989.
14. Effects of Cocaine on Pregnancy. Abuses During Pregnancy. Maternal Infant Care Continuing Education Program. Gainesville, FL, October 30, 1989.
- 14a. Legal Issues of Reporting-Panel Discussion. Maternal Infant Care Continuing Education Program. Gainesville, FL, October 30, 1989.

15. Prenatal Cocaine use and Its Effect on the Infant. Clinical Laboratory Continuing Education Program. Gainesville, FL, November 21, 1989.
16. Drug Abuse in Mothers. Twelfth Annual Management of the Tiny Baby. Orlando, FL, February 8-10, 1990.
17. Caring for Cocaine Babies. Workshop. Cocaine☐ Innocent Casualties. Ocala, FL, June 26, 1990.
18. Summary of Conference and Challenges for the Future. Cocaine☐ Innocent Casualties. Ocala, FL, June 26, 1990.
19. Prenatal Substance Abuse: An Innocent Generation at Risk. Strategies for Success: Linking Disciplines to Effect Change in Children. Gainesville, FL January 24, 1991.
20. Maternal Substance Abuse in Rural Florida. Substance Abuse and Pregnancy: Children Deserve Better. Clearwater Beach, FL, February 6-8, 1991.
21. Prenatal Substance Abuse in North Central Florida. Nutrition for Mothers and Infants at Risk. Tampa, FL, April 29-30, 1991.
22. An Interdisciplinary Early Intervention Model. New Directions, New Dimensions - Caregiving in the 1990's. Tampa, FL, June 21-23, 1991.
23. Prenatal Cocaine Use and Infant Outcome: Separating Fact and Fiction. Pediatric Grand Rounds, Gainesville, FL, August 30, 1991.
24. Outcome of LBWI with Intracranial Hemorrhage. Pediatric Residents Core Curriculum. Gainesville, FL, November 26, 1991.
25. Low Birth Weight Infants: Intracranial Bleeds. Today☐ Child...Tomorrow☐ Future. Gainesville, FL, December 5-6, 1991.
26. You Have Taken My Baby: Grief Reactions in Parents. Fifth Annual Neonatal Stabilization and Transport Symposium. Orlando, FL, November 10-13, 1992.
27. Substance Abuse During Pregnancy: Who, What, When, Where, and Why. Addiction Medicine: Managing Patients Who Live Dangerously. Orlando, FL, January 15-17, 1993.
28. Substance Abuse During Pregnancy: Effects on an Innocent Generation. Addiction Medicine: Managing Patients Who Live Dangerously. Orlando, FL, January 15-17, 1993.
29. Research Issues and Findings in the Study of Prenatal Cocaine Exposure. OB-GYN Grand Rounds. Gainesville, FL, January 29, 1993.
30. Building Stronger Families: Putting Prenatal Substance Use in Perspective in the Rural South. Redefining the Family: Children Deserve Better. St. Petersburg Beach, FL, February 4-6, 1993.
31. Prenatal Substance use: Its Effect on the Fetus, Newborn, and Child. Pediatric Grand Rounds. Gainesville, FL, June 4, 1993.
32. Effective Parental Rapport and Support. Sixth Annual Neonatal Stabilization and Transport Symposium. Orlando, FL, November 2-5, 1993.
33. All That Jitters is Not Gold in Neonatology Pearls. Pediatric Grand Rounds. Gainesville, FL December 17, 1993.

34. Long-term Outcome of the Drug-Exposed Fetus. Neonatal Advanced Physiology Course, Part VII. Gainesville, FL, June 6, 1994.
35. Cocaine Use Among Rural Pregnant Women: Focus on Birth Outcome. Second Annual Florida Rural Health Association Conference. Tampa, FL, September 21-23, 1994.
36. Perinatal Effects of Cocaine. Perinatal Outreach Program. Leesburg, FL, April 14, 1995.
37. Identification and Treatment of Substance-Exposed Children. Hamilton County School Teachers In-Service. Jennings, FL, May 24, 1995.
38. Medical Outcomes of Cocaine-Exposed Babies. Epidemiology and Public Health Research in Florida: Current Work and Anticipated Needs. Gainesville, FL, July 20-21, 1995.
39. Cocaine Use Among Rural Pregnant Women. Sharing Solutions IV: Coordinating Care. Orlando, FL, November 30-December 1, 1995.
40. Drugs in the Perinatal patient. Pediatric Residents Core Curriculum. Gainesville, FL, January 10, 1996.
41. Prenatal Substance Exposure and Its Effect on the Developing Fetus and Child. Health and Rehabilitative Services In-Service. Gainesville, FL, May 31, 1996.
42. Update on Prenatal Cocaine Exposure: Is There Fire Where There's Smoke? Pediatric Grand Rounds, Gainesville, FL, June 21, 1996.
43. The Effects of Substances of Abuse on Pregnancy Outcome. HUD-3 Study Section, Washington, D.C., November 6, 1997.
44. Prenatal Substance Abuse. Healthy Families Alachua, Gainesville, FL, December 1, 1999.
45. Does Prenatal Cocaine Exposure Provide a Roadmap to Outcome: What Have We Learned from Neonates and Young Children? Early Childhood Neurobehavioral Assessment for the Differential Diagnosis of Fetal Alcohol Syndrome and Alcohol-Related Neurodevelopmental Disorder, NIAAA, Washington, D.C., March 8-10, 2000.
46. Prenatal Substance Use and Long-Term Outcome. 24th Annual Management of the Tiny Baby Conference, Orlando, FL, February 14-16, 2002.
47. Substance Exposed Infants: Short and Long-term Impact. 27th Annual Conference of the National Association of Perinatal Social Workers, Orlando, FL, May 1, 2003.
48. Prenatal Cocaine Exposure: Results from a Longitudinal, Prospective Study. Department of Psychiatry Research Conference, Gainesville, FL, August 25, 2003.
49. Neuroimaging of Prenatally Cocaine-Exposed Children. Long-Term Follow-up of Prenatal Drug Exposure: Advances, Challenges, and Opportunities, NIDA/NICHD Conference, Washington, D.C., March 23-24, 2004.
50. Neuroimaging Findings in Prenatally Cocaine-exposed Children. Neurobehavioral Teratology Society Annual Meeting, Invited Symposium on Neuroimaging in Prenatal Drug Exposure, Vancouver, BC, June, 2004.
51. Prenatal Cocaine Exposure: A Prospective, Longitudinal Study. Veterinary Medicine Graduate Seminar, Gainesville, FL, March 15, 2005.

52. Understanding Drug Effects in Children with Prenatal Cocaine Exposure. American Society of Addiction Medicine, Washington, DC, October 2005.
53. Diffusion Tensor Imaging of Frontal White Matter & Executive Functioning in Cocaine-Exposed Children. National Institute on Drug Abuse, Washington, DC, March 2007.
54. Prenatal Cocaine Exposure: What Have We Learned Over the Past 20 Years? A Day with the Newborn, Philadelphia, PA, January, 2008.
55. Prenatal Substance Exposure and Its Long-term Outcomes on Development and Behavior. National Conference and Exhibition, American Academy of Pediatrics, October 2008.
56. Prenatal Drug Exposure and Brain Development: Outcomes from a Prospective Longitudinal Study of Prenatal Cocaine Exposure. National Conference and Exhibition, American Academy of Pediatrics, October 2008.
57. Recognizing and Treating Neonatal Withdrawal in the 21st Century. National Conference and Exhibition, American Academy of Pediatrics, October 2009.
58. Drug Use, Pregnancy & Parenting: What Does the Science Tell Us? Lunch and Learn Seminar for New York State Family Court, April 2010.
59. Effects of Prenatal Drug Use on Short and Long-term Outcome. Roosevelt Hospital Faculty Seminar, New York City, April 2010.
60. Drug Use, Pregnancy & Parenting: What Does the Science Tell Us? Drugs, Pregnancy, and Parenting: What the Experts Have to Say, National Advocates for Pregnant Women, New York City, April 2010.
61. Drug Exposed Infants: Trends and Challenges. National Rx Drug Abuse Summit, Orlando, FL, April 2012.
62. Opiate Use by Pregnant Women: The Short and Long-term Effects on Babies and Children. Florida Alcohol and Drug Abuse Association Webinar, June, 2012.
63. Opioid Use During Pregnancy: Treatment Strategies for Women, Babies, and Children. Florida Alcohol and Drug Abuse Association/Florida Council for Community Mental Health Annual Meeting, Orlando, FL, August, 2012.